Dr Reddy's Labs Among First to Launch Generic Semaglutide in Canada
New Delhi: Drugmaker Dr. Reddy's Laboratories has announced the launch of its generic Semaglutide Injection in Canada following the receipt of a Notice of Compliance (NOC) from Health Canada on April 28, 2026. The company said it is among the first pharmaceutical firms to introduce a generic semaglutide injection in the Canadian market.
According to the company, Canada has become the first G7 nation to grant market authorization for a generic semaglutide injection, marking a significant milestone in expanding access to GLP-1 therapies.
Dr. Reddy’s stated that the once-weekly injectable therapy is indicated for adults with type 2 diabetes mellitus to improve glycemic control in combination with diet and exercise.
The product will be available as a sterile solution for subcutaneous injection in pre-filled pen formats of 2 mg/pen and 4 mg/pen strengths. The 2 mg pen delivers 0.25 mg or 0.5 mg doses, while the 4 mg pen is designed for 1 mg doses.
Commenting on the launch, Erez Israeli, Chief Executive Officer of Dr. Reddy’s Laboratories, said, “We are pleased to launch our generic Semaglutide Injection in Canada, within days of receiving Health Canada approval. The milestone highlights our readiness to serve Canadian patients, supported by our deep expertise in complex drug and peptide development.”
He further added, “With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients. The Canada launch builds on the momentum of our recent launch in India under the brand name Obeda®. As GLP-1 therapies continue to be a key focus area for us, we are actively working to expand access across multiple global markets.”
The company noted that semaglutide injection is approved for use either alone or in combination with other anti-diabetic therapies, including metformin, sulfonylureas, SGLT2 inhibitors, and basal insulin in eligible patients with type 2 diabetes.
Dr. Reddy’s clarified that the medicine is not intended for use in patients with type 1 diabetes mellitus or diabetic ketoacidosis and should not be considered a substitute for insulin therapy.
